ClinicalTrials.gg
Drug

E-3810 clinical trials

Also written Lucitanib, AL3810 and E-3810.

studies test it
14
open now
0
in phase 3
4
first study started
2004

How each study uses E-3810 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

E3810
2

Development codes

AL3810
4
E-3810
2
CO-3810
2

Other names

Lucitanib
8

In one entry with another drug

Given together, or one or the other

E3810
4

Studies by the year they started

14 studies that test it; most in 2014 (3)

Studies that test E-3810, by start year
YearStudies
20041
20081
20102
20111
20131
20143
20172
20181
20192

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
10
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 11 · Other 3

Haihe Biopharma Co., Ltd. (4) · Eisai Co., Ltd. (3) · Clovis Oncology, Inc. (3) · Institut de Recherches Internationales Servier (2) · Eisai Inc. (1) · Teresa Helsten, MD (1)

Often tested with

Tested in the same studies.

Rabeprazole (4)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses E-3810 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 14

Given beside what is tested · 2 — E-3810 is usual care or a partner of the new treatment